8 results  1 of 1 

1 Genomics of diffuse large B cell lymphoma
Youngil Koh
Blood Res.2021;56(S1):75-79.   Published online 2021 April 30     DOI: http://dx.doi.org/10.5045/br.2021.2021049
      
2 Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
Do Young Kim, Jehyun Nam, Joo-seop Chung, Sang-Woo Kim, Ho-Jin Shin
Cancer Res Treat.2022;54(1):301-313.   Published online 2021 April 27     DOI: http://dx.doi.org/10.4143/crt.2020.1371
      
3 Curcumin Inhibits the Proliferation, Migration, Invasion, and Apoptosis of Diffuse Large B-Cell Lymphoma Cell Line by Regulating MiR-21/VHL Axis
Ling Chen, Cheng-Zhi Zhan, Tao Wang, Hua You, Rui Yao
Yonsei Med J.2020;61(1):20-29.   Published online 2019 December 23     DOI: http://dx.doi.org/10.3349/ymj.2020.61.1.20
      
4 Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
Do-Young Kim, Moo-Kon Song, Joo-Seop Chung, Ho-Jin Shin, Deok Hwan Yang, Sung-Nam Lim, Sung-Yong Oh
Blood Res.2019;54(4):244-252.   Published online 2019 December 20     DOI: http://dx.doi.org/10.5045/br.2019.54.4.244
      
5 Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma
Mahsa Eskandari, Saba Manoochehrabadi, Hossein Pashaiefar, Mohammad Ali Zaimy, Mohammad Ahmadvand
Blood Res.2019;54(2):114-119.   Published online 2019 June 25     DOI: http://dx.doi.org/10.5045/br.2019.54.2.114
      
6 Prognostic Significance of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Lee Chun Park, Ho Sup Lee, Eun Mi Lee, Seong Hoon Shin, Yang Soo Kim
Kosin Med J.2016;31(2):122-133.   Published online 2016 January 20     DOI: http://dx.doi.org/10.7180/kmj.2016.31.2.122
   
7 Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
Sukjoong Oh, Dong Hoe Koo, Cheolwon Suh, Shin Kim, Bong Hee Park, Joon Kang, Jooryung Huh
J Korean Med Sci.2011;26(12):1556-1562.   Published online 2011 November 29     DOI: http://dx.doi.org/10.3346/jkms.2011.26.12.1556
      
8 Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea
Ock Bae Ko, Shin Kim, Dae Ho Lee, Sang We Kim, Jooryung Huh, Cheolwon Suh
Korean J Hematol.2007;42(4):309-316.   Published online 2007 January 19     DOI: http://dx.doi.org/10.5045/kjh.2007.42.4.309
   

 1 of 1